Page 2 - Claritas Mybestsegment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Claritas mybestsegment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Claritas Mybestsegment Today - Breaking & Trending Today

Claritas Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation

SAN FRANCISCO and TORONTO, June 10, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has received commitments from the Company’s two largest shareholders to vote in favor of the special resolution to affect a consolidation of the Company’s common shares. As previously announced, Claritas will hold its Annual General and Special Meeting of Shareholders on June 17, 2021 (the “Annual Meeting”) t ....

Claritas Pharmaceuticals , Common Shares , Share Consolidation , Claritas Pharmaceuticals , Institutional Investors , Special Resolution ,

Centriply + Claritas, now enabling data-driven linear TV ad campaigns at the household level.

Advanced Linear TV advertising agency Centriply, announced today a collaborative effort with Claritas® to help brands maximize their linear TV ad campaigns. The agreement between the two integrates Claritas audiences with TV inventory data, which enables brands to create meaningful interactions with valuable TV audiences at the household, local or national level. When paired with audience profiling capabilities, brands can leverage the right targeting to increase growth and profitability, utiliz ....

Tv Audiences , Audience Data , Inventory Data , Customer Segments , Marketing Channels , Dvertising Agency Centriply , Jeff Lewis , Tv Ad Campaigns ,

Kalytera Announces Resumption of Trading on TSXV

Company Will Change Its Name to Claritas Pharmaceuticals and Launch New WebsiteSAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that its shares will resume trading today on the TSX VENTURE EXCHANGE (“TSXV”). The Company also announced that, pending TSXV approval, it will change its name to Claritas Pharmaceuticals, Inc. The Company is also pleased to announce the launch of its new website at http://www.claritaspharma.com/. The decision to rename the Company signals the re-launch of the Company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 as well as other viral infections. R-107 is a nitric oxide releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the viruses that cause influenza and the common cold. The Company’ ....

The Company , Tsx Venture Exchange , Viral Infections , Nitric Oxide , Name Change , Kalytera Therapeutics , Robert Farrell , Ticker Symbol , தி நிறுவனம் , ட்சிக்ஷ துணிகர பரிமாற்றம் , வைரஸ் நோய்த்தொற்றுகள் , பெயர் மாற்றம் , ராபர்ட் ஃப்யாரெல் , டிக்கர் சின்னம் ,